Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer
Metrics: PDF 1413 views | HTML 2085 views | ?
Mingwei Chen1, Jianfa Li2, Chengle Zhuang3, Zhiming Cai2
1Department of Urology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu 322000, Zhejiang, China
2Shantou University Medical College, Shantou 515041, Guangdong, China
3Peking University Shenzhen Hospita, Shenzhen 518036, Guangdong, China
Mingwei Chen, email: email@example.com
Keywords: ABHD11-AS1, bladder cancer, lncRNAs, proliferation, migration
Received: October 09, 2016 Accepted: January 10, 2017 Published: February 01, 2017
Bladder cancer is one of the most common urothelial tumors worldwide. While there are some progresses on early bladder cancer detection, patients’ mortalities have not been changed significantly. So it is important to get further understanding the mechanism involved in the development and progression of bladder cancer. Long non-coding RNAs play important regulatory roles in a variety of biological processes ranging from gene regulation, cellular differentiation to tumorigenesis. Previous literatures reported that lncRNA ABHD11 Antisense RNA 1 (ABHD11-AS1) (Organism: Homo sapiens) was highly expressed in gastric cancer. Inspired by these observations, we hypothesized that ABHD11-AS1 possibly plays an analogous role in human bladder cancer. We first found that ABHD11-AS1 was up-regulated in bladder cancer tissues and cell lines, and ABHD11-AS1 expression level was positively associated with clinicobiological features. Cell proliferation, cell migration and apoptosis were observed by silencing ABHD11-AS1 and overexpression ABHD11-AS1 caused contrary effects. Taken together, these data suggested that ABHD11-AS1 may be an oncogene and a therapeutic target in bladder cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.